Specifically, tumor cells infected with oncolytic viruses or transduced with viral vectors produce EVs that carry tumor antigens along with endogenous danger‐associated signals or engineered immune‐stimulatory cues, thereby significantly enhancing immunogenicity.[76] These EVs activate innate immune receptors such as TLR3 and RIG‐I, concurrently delivering TAAs to APCs for efficient cross‐priming. Here, TLR3 is linked to neoplasm.